Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening.

Ke Y, Taylor J, Gao L, Wang H, Zhao H, Byrne N, Modgil V, Butaney M, Makarov DV, Prabhu V, Loeb S.

BJU Int. 2019 Feb 27. doi: 10.1111/bju.14734. [Epub ahead of print] No abstract available.

PMID:
30811805
2.

Variation in collagenase Clostridium histolyticum practice patterns: a Survey of ISSM Members.

Masterson TA, Galante A, Butaney M, Pastuszak A, Sadeghi-Nejad H, Ramasamy R.

Int J Impot Res. 2019 Feb 12. doi: 10.1038/s41443-019-0126-y. [Epub ahead of print]

PMID:
30755724
3.

Current practice in the management of ischemic priapism: an anonymous survey of ISSM members.

Butaney M, Thirumavalavan N, Rodriguez D, Gross MS, Munarriz R.

Int J Impot Res. 2019 Feb 4. doi: 10.1038/s41443-019-0120-4. [Epub ahead of print]

PMID:
30718828
4.

Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination.

Loeb S, Taylor J, Butaney M, Byrne NK, Gao L, Soule HR, Miyahira AK.

Eur Urol. 2019 May;75(5):881-882. doi: 10.1016/j.eururo.2019.01.025. Epub 2019 Jan 31. No abstract available.

PMID:
30711329
5.

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.

Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

JAMA Oncol. 2019 Jan 3. doi: 10.1001/jamaoncol.2018.5904. [Epub ahead of print]

PMID:
30605213
6.

Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.

Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.

Eur Urol. 2019 Apr;75(4):564-567. doi: 10.1016/j.eururo.2018.10.056. Epub 2018 Nov 28.

PMID:
30502104
7.

Urinary Biomarkers in the Evaluation of Primary Hematuria: A Systematic Review and Meta-Analysis.

Sathianathen NJ, Butaney M, Weight CJ, Kumar R, Konety BR.

Bladder Cancer. 2018 Oct 29;4(4):353-363. doi: 10.3233/BLC-180179. Review.

8.

Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis.

Sathianathen NJ, Butaney M, Bongiorno C, Konety BR, Bolton DM, Lawrentschuk N.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):39-48. doi: 10.1038/s41391-018-0075-4. Epub 2018 Aug 14.

PMID:
30108376
9.

Variability in penile duplex ultrasound international practice patterns, technique, and interpretation: an anonymous survey of ISSM members.

Butaney M, Thirumavalavan N, Hockenberry MS, Kirby EW, Pastuszak AW, Lipshultz LI.

Int J Impot Res. 2018 Oct;30(5):237-242. doi: 10.1038/s41443-018-0061-3. Epub 2018 Aug 14.

10.

The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.

Sathianathen NJ, Butaney M, Konety BR.

World J Urol. 2019 Jul;37(7):1239-1249. doi: 10.1007/s00345-018-2403-7. Epub 2018 Jul 12.

PMID:
30003375
11.

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA.

J Thorac Oncol. 2015 Dec;10(12):1726-35. doi: 10.1097/JTO.0000000000000687.

12.

Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.

Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo MEB, Ambrogio C, Wang Q, Minero VG, Poggio T, Martinengo C, D'Amico L, Panizza E, Mologni L, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R.

Cancer Immunol Res. 2015 Dec;3(12):1333-1343. doi: 10.1158/2326-6066.CIR-15-0089. Epub 2015 Sep 29.

13.

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

Tanizaki J, Ercan D, Capelletti M, Dodge M, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, Hammerman PS, Oxnard GR, Wong KK, Jänne PA.

Cancer Res. 2015 Aug 1;75(15):3139-46. doi: 10.1158/0008-5472.CAN-14-3771. Epub 2015 Jun 5.

14.

A functional landscape of resistance to ALK inhibition in lung cancer.

Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, Meyerson M, Root DE, Jänne PA, Garraway LA.

Cancer Cell. 2015 Mar 9;27(3):397-408. doi: 10.1016/j.ccell.2015.02.005.

15.

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Jänne PA.

Clin Cancer Res. 2015 Jun 15;21(12):2851-60. doi: 10.1158/1078-0432.CCR-14-3112. Epub 2015 Mar 3.

16.

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W 3rd, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA.

Cell Rep. 2014 Jun 26;7(6):1824-32. doi: 10.1016/j.celrep.2014.05.039. Epub 2014 Jun 12.

17.

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA.

Clin Cancer Res. 2014 Mar 15;20(6):1698-1705. doi: 10.1158/1078-0432.CCR-13-2482. Epub 2014 Jan 15.

18.

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC.

Nat Med. 2013 Nov;19(11):1469-1472. doi: 10.1038/nm.3352. Epub 2013 Oct 27.

19.

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK.

Cancer Discov. 2013 Dec;3(12):1355-63. doi: 10.1158/2159-8290.CD-13-0310. Epub 2013 Sep 27.

20.

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.

Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ.

Am J Surg Pathol. 2013 Sep;37(9):1441-9. doi: 10.1097/PAS.0b013e3182960fa7.

21.

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA.

Clin Cancer Res. 2013 Aug 15;19(16):4532-40. doi: 10.1158/1078-0432.CCR-13-0657. Epub 2013 Jul 5.

22.

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA.

J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

23.

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.

J Thorac Oncol. 2012 Dec;7(12):1767-1774. doi: 10.1097/JTO.0b013e3182745bcb.

24.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA.

Cancer Discov. 2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7.

25.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.

26.

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Jänne PA, Hahn WC.

Cancer Discov. 2011 Dec;1(7):608-25. doi: 10.1158/2159-8290.CD-11-0046. Epub 2011 Oct 17.

27.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Jänne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK.

Nature. 2012 Mar 18;483(7391):613-7. doi: 10.1038/nature10937.

28.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR.

Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.

29.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA.

Cancer Res. 2011 Sep 15;71(18):6051-60. doi: 10.1158/0008-5472.CAN-11-1340. Epub 2011 Jul 26.

Supplemental Content

Loading ...
Support Center